
Tolerx
closedNovel therapies that modulate T-cell activities to treat patients with autoimmune diseases, diabetes and cancer.
Employees
Enterprise value
$6—9m
Authorizing premium user...
Novel therapies that modulate T-cell activities to treat patients with autoimmune diseases, diabetes and cancer.